This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wu, X. Articles by Spitz, M. R. Search for Related Content PubMed PubMed Citation Articles by Wu, X. Articles by Spitz, M. R.

Serum Levels of Insulin Growth Factor (IGF-I) and IGF-Binding Protein Predict Risk of Second Primary Tumors in Patients with Head and Neck Cancer

Departments of ¹ Epidemiology, ² Biostatistics and ³ Thoracic and Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

ABSTRACT

Purpose: Second primary tumors (SPTs) are a hallmark of head and neck squamous cell carcinomas (HNSCCs). Serum levels of insulin growth factors (IGFs) and their binding proteins (IGFBPs) have been associated with subsequent development of several epithelial cancers in prospective studies.

Experimental Design: To examine the role of IGFs in SPT development, we conducted a nested case–control study within a randomized, placebo-controlled chemoprevention trial in patients with early-stage HNSCC. We compared prediagnostic serum IGF-I and IGFBP-3 levels in 80 patients who subsequently developed SPTs and 173 controls (patients without SPTs) matched to the cases on age (±5 years), sex, ethnicity, year of randomization, and length of follow-up.

Results: The cases exhibited significantly higher levels of IGF-I and IGFBP-3 than did the controls (P = 0.001 and 0.019, respectively). Elevated IGF-I levels were associated with a 3.66-fold significantly increased risk of SPT. Lower and higher IGFBP-3 levels were associated with a 2.22- and 7.12-fold significant increased risk, respectively. The median SPT-free time was significantly shorter in patients with higher IGF-I levels than in patients with lower IGF-I levels (P < 0.0001). A similar trend was observed for IGFBP-3 (P = 0.002). Moreover, in the Cox proportional hazards model, higher IGF-I levels were significantly associated with increased risk of SPT with a hazard ratio of 2.78. Patients with the lower and higher IGFBP-3 levels also exhibited significantly increased risks with hazard ratios of 1.65 and 2.17, respectively.

Conclusions: This is the first study demonstrating that higher IGF-I levels, and lower and higher IGFBP-3 levels are risk factors for SPT development. Thus, measuring serum IGF-I and IGFBP-3 levels may be useful markers in assessing the risk of second tumors in patients successfully treated for their index cancer.

This article has been cited by other articles:

				S. Min Park, M. Kyung Lim, K. Won Jung, S. Ae Shin, K.-Y. Yoo, Y. Ho Yun, and B. Yul Huh Prediagnosis Smoking, Obesity, Insulin Resistance, and Second Primary Cancer Risk in Male Cancer Survivors: National Health Insurance Corporation Study J. Clin. Oncol., October 20, 2007; 25(30): 4835 - 4843. [Abstract] [Full Text] [PDF]

				X. Wu, J. Gu, Q. Dong, M. Huang, K.-A. Do, W. K. Hong, and M. R. Spitz Joint Effect of Mutagen Sensitivity and Insulin-Like Growth Factors in Predicting the Risk of Developing Secondary Primary Tumors and Tumor Recurrence in Patients with Head and Neck Cancer Clin. Cancer Res., December 1, 2006; 12(23): 7194 - 7201. [Abstract] [Full Text] [PDF]

				S. J. Freemantle, K. H. Dragnev, and E. Dmitrovsky The retinoic Acid paradox in cancer chemoprevention. J Natl Cancer Inst, April 5, 2006; 98(7): 426 - 427. [Full Text] [PDF]

				M. M. Kibbey, M. J. Jameson, E. M. Eaton, and S. A. Rosenzweig Insulin-Like Growth Factor Binding Protein-2: Contributions of the C-Terminal Domain to Insulin-Like Growth Factor-1 Binding Mol. Pharmacol., March 1, 2006; 69(3): 833 - 845. [Abstract] [Full Text] [PDF]

				S.-H. Oh, W.-Y. Kim, J.-H. Kim, M. N. Younes, A. K. El-Naggar, J. N. Myers, M. Kies, P. Cohen, F. Khuri, W. K. Hong, et al. Identification of Insulin-Like Growth Factor Binding Protein-3 as a Farnesyl Transferase Inhibitor SCH66336-Induced Negative Regulator of Angiogenesis in Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., January 15, 2006; 12(2): 653 - 661. [Abstract] [Full Text] [PDF]